Loading
Life sciences · Journal article
iScience · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
BRAF-mutant non-small cell lung cancer (NSCLC) comprises three functional classes (I–III) with distinct driving mechanisms, yet effective therapies for classes II and III remain limited. To address this, we developed a quantitative systems pharmacology (QSP) model that mechanistically recapitulates signaling networks and drug responses across all three classes, integrating multiscale preclinical-to-clinical datasets. The model enabled high-throughput prediction of clinical efficacy for monotherapies and combination therapies across diverse dosing regimens, and we identified that combining MEK and ERK inhibition represents a novel strategy for class II/III mutants, validated by original in vivo MiniPDX data using NSCLC patient tumors. Simulations further revealed that only triple blockade of EGFR, IGF1R, and FGFR pathway initiation can potently reduce tumor growth and overcome resistance in these classes. Our work is the first multiscale QSP platform mechanistically addressing class I–III BRAF mutations at the systems level for disease-centric translational combination therapy discovery and precision medicine design.